Attributes | Values |
---|
rdf:type
| |
Description
| - The present invention relates to a compound of formula I, or a pharmaceutically acceptable acid salt thereof. The invention further relates to the use of such compounds in the treatment of hyperproliferative skin disorders, viral infections, cancer, rheumatoid arthritis, lupus, type I diabetes, multiple sclerosis, restenosis, polycystic kidney disease, graft rejection, graft versus host disease and gout, or for psoriasis, parasitoses such as those caused by fungi or protists, or Alzheimer's disease.Further aspects of the invention relate to the use of such compounds in the inhibition of cell proliferation, in the induction of apoptosis, to modulate the activity of adrenergic and/or purinergic receptors or to suppress immunostimulation. The invention also relates to the use of 2,6,9-trisubstituted 8-azapurines in maintaining mammalian ooctyes at the germinal vesicle stage.
- The present invention relates to a compound of formula I, or a pharmaceutically acceptable acid salt thereof. The invention further relates to the use of such compounds in the treatment of hyperproliferative skin disorders, viral infections, cancer, rheumatoid arthritis, lupus, type I diabetes, multiple sclerosis, restenosis, polycystic kidney disease, graft rejection, graft versus host disease and gout, or for psoriasis, parasitoses such as those caused by fungi or protists, or Alzheimer's disease.Further aspects of the invention relate to the use of such compounds in the inhibition of cell proliferation, in the induction of apoptosis, to modulate the activity of adrenergic and/or purinergic receptors or to suppress immunostimulation. The invention also relates to the use of 2,6,9-trisubstituted 8-azapurines in maintaining mammalian ooctyes at the germinal vesicle stage. (en)
|
Title
| - Substituted [1,2,3]triazolo[4,5-D]pyrimidines as CDK inhibitors
- Substituted [1,2,3]triazolo[4,5-D]pyrimidines as CDK inhibitors (en)
|
skos:prefLabel
| - Substituted [1,2,3]triazolo[4,5-D]pyrimidines as CDK inhibitors
- Substituted [1,2,3]triazolo[4,5-D]pyrimidines as CDK inhibitors (en)
|
skos:notation
| - RIV/61389030:_____/10:00353545!RIV11-GA0-61389030
|
http://linked.open...avai/riv/aktivita
| |
http://linked.open...avai/riv/aktivity
| - P(GA301/08/1649), P(KAN200380801)
|
http://linked.open...cisloPatentuVzoru
| |
http://linked.open...eleniPatentuVzoru
| |
http://linked.open...vai/riv/dodaniDat
| |
http://linked.open...aciTvurceVysledku
| |
http://linked.open.../riv/druhVysledku
| |
http://linked.open...iv/duvernostUdaju
| |
http://linked.open...titaPredkladatele
| |
http://linked.open...dnocenehoVysledku
| |
http://linked.open...ai/riv/idVysledku
| - RIV/61389030:_____/10:00353545
|
http://linked.open...riv/jazykVysledku
| |
http://linked.open.../riv/klicovaSlova
| - Substituted [1,2,3]triazolo[4,5-D]pyrimidines; CDK; inhibitors (en)
|
http://linked.open.../riv/klicoveSlovo
| |
http://linked.open...ontrolniKodProRIV
| |
http://linked.open.../licencniPoplatek
| |
http://linked.open...ydaniPatentuVzoru
| |
http://linked.open...atelePatentuVzoru
| - United States Patent and Trademark Office http://v3.espacenet.com/publicationDetails/originalDocument?FT=D&date=20101019&DB=EPODOC&locale=en_EP&CC=US&NR=7816350B2&KC=B2
|
http://linked.open...in/vavai/riv/obor
| |
http://linked.open...ichTvurcuVysledku
| |
http://linked.open...cetTvurcuVysledku
| |
http://linked.open...vavai/riv/projekt
| |
http://linked.open...UplatneniVysledku
| |
http://linked.open...ydaniPatentuVzoru
| |
http://linked.open...iv/tvurceVysledku
| - Havlíček, Libor
- Kryštof, Vladimír
- Strnad, Miroslav
- Lenobel, René
- Fuksová, Květa
|
http://linked.open...mniOchranaPatentu
| |
http://linked.open...avai/riv/vlastnik
| |
http://linked.open...itiJinymSubjektem
| |
http://linked.open...uzitiPatentuVzoru
| |
http://linked.open...stnikPatentuVzoru
| - Ústav experimentální botaniky AV ČR, v. v. i., Univerzita Palackého v Olomouci
|